Stereotactic body radiotherapy for an isolated splenic metastasis from ovarian carcinoma.
isolated splenic metastasis
ovarian carcinoma
spleen metastasis
stereotactic body radiotherapy
Journal
Journal of radiosurgery and SBRT
ISSN: 2156-4647
Titre abrégé: J Radiosurg SBRT
Pays: United States
ID NLM: 101565296
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
24
10
2019
pubmed:
24
10
2019
medline:
24
10
2019
Statut:
ppublish
Résumé
Splenic metastases from oligometastatic ovarian carcinoma are a rare occurrence. Usual treatment for splenic metastases includes splenectomy, but some patients are either unable or unwilling to undergo surgery. Stereotactic body radiotherapy (SBRT) is an effective ablative modality for treating metastatic disease. SBRT to abdominopelvic tumors has been shown to be safe and effective for properly-selected patients and is particularly attractive in the oligometastatic setting as an alternative to radical resection. In this case study, we report a patient with an isolated splenic metastasis from ovarian carcinoma treated with 50 Gy in 10 fractions.
Types de publication
Journal Article
Langues
eng
Pagination
161-163Informations de copyright
© 2019 Old City Publishing, Inc.
Déclaration de conflit d'intérêts
Authors’ disclosure of potential conflicts of interest The authors have nothing to disclose. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.
Références
Int J Gynecol Cancer. 2003 Mar-Apr;13(2):125-9
pubmed: 12657111
Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):527-535
pubmed: 30003996
J Cancer Res Clin Oncol. 2009 May;135(5):667-71
pubmed: 18936972
Exp Ther Med. 2014 Apr;7(4):982-986
pubmed: 24669262
Arch Pathol Lab Med. 2000 Apr;124(4):526-30
pubmed: 10747308
Cancer. 1987 Jul 1;60(1):100-2
pubmed: 3581023
Clin Oncol (R Coll Radiol). 2018 Jan;30(1):5-14
pubmed: 29033164
JAMA Oncol. 2018 Jan 11;4(1):e173501
pubmed: 28973074
Lancet Oncol. 2016 Dec;17(12):1672-1682
pubmed: 27789196